Latest News

Aspirin Use Does Not Reduce Risk of Colorectal Cancer Recurrence

Aspirin Use Does Not Reduce Risk of Colorectal Cancer Recurrence

There was no evidence that aspirin use beginning at the onset of chemotherapy affected the risk of recurrence among patients with stage II or III colorectal cancer.

Regorafenib Improves Overall Survival in Liver Cancer

Regorafenib Improves Overall Survival in Liver Cancer

Second-line systemic therapy with regorafenib improves overall survival among patients with hepatocellular carcinoma (HCC).

Adding Ruxolitinib to Capecitabine Fails To Improve Outcomes in Pancreatic Cancer

Adding Ruxolitinib to Capecitabine Fails To Improve Outcomes in Pancreatic Cancer

Addition of ruxolitinib to second-line capecitabine therapy was well tolerated but did not improve clinical outcomes.

GEMOX Does Not Improve Relapse-free Survival in Biliary Tract Cancer

GEMOX Does Not Improve Relapse-free Survival in Biliary Tract Cancer

GEMOX post-surgery adjuvant therapy does not improve relapse-free survival (RFS) among patients with biliary tract cancer.

FDA Approves Ibrutinib for Rare Type of NHL

FDA Approves Ibrutinib for Rare Type of NHL

The FDA has granted accelerated approval to ibrutinib (Imbruvica) for the treatment of patients with relapsed/refractory marginal zone lymphoma.

ASCO Releases Guideline for the Management of Small Renal Masses

ASCO Releases Guideline for the Management of Small Renal Masses

ASCO published new recommendations for the management of patients with clinically localized small renal masses (SRMs).

Lung Cancer Risk Assessment Should Include Lung Function Assessment

Lung Cancer Risk Assessment Should Include Lung Function Assessment

Lung cancer screening programs may be improved with the use of risk prediction models that incorporate lung function.

Advanced Pancreatic Cancer: 3 New Agents Improved Outcomes Between 1978-2015

Advanced Pancreatic Cancer: 3 New Agents Improved Outcomes Between 1978-2015

Phase 2 trials of investigational agents for pancreatic cancer treatment do not usually progress to phase 3.

Bursectomy Not Recommended as Standard Treatment for cT3/T4 Gastric Cancer

Bursectomy Not Recommended as Standard Treatment for cT3/T4 Gastric Cancer

Bursectomy can be safely performed without increasing the risk of morbidity or mortality among patients with cT3 or cT4 gastric cancer.

Ramucirumab Efficacious Regardless of Age in Gastric Cancer

Ramucirumab Efficacious Regardless of Age in Gastric Cancer

For patients with advanced gastric cancer, second-line treatment with ramucirumab is safe and efficacious regardless of age.

Nivolumab Efficacious as Salvage Therapy for Advanced Gastric Cancer

Nivolumab Efficacious as Salvage Therapy for Advanced Gastric Cancer

Salvage therapy with nivolumab was efficacious among patients with advanced or recurrent gastric or gastroesophageal junction (GEJ) cancer.

Adding Everolimus to Paclitaxel Not Effective for Advanced Gastric Cancer

Adding Everolimus to Paclitaxel Not Effective for Advanced Gastric Cancer

The addition of everolimus to paclitaxel did not significantly improve overall response rate, progression-free survival, or overall survival.

Venetoclax is Well Tolerated, Active in Non-Hodgkin Lymphoma

Venetoclax is Well Tolerated, Active in Non-Hodgkin Lymphoma

Venetoclax was well-tolerated with variable efficacy against various non-Hodgkin lymphoma (NHL) subtypes.

Acute Coronary Events After Radiotherapy in Breast Cancer

Acute Coronary Events After Radiotherapy in Breast Cancer

The volume of the left ventricle receiving 5 Gy (LV-V5) during radiotherapy (RT) predicted an increased risk of acute coronary events (ACE).

Quality of Life Changes Linked to Aromatase Inhibitor Nonadherence in Breast Cancer

Quality of Life Changes Linked to Aromatase Inhibitor Nonadherence in Breast Cancer

Chemoprevention for breast cancer is vastly underused, and those who are on regimens for prevention are generally nonadherent.

Event-free Survival at 24 Months as a Surrogate Endpoint for DLBCL

Event-free Survival at 24 Months as a Surrogate Endpoint for DLBCL

Patients with diffuse large B-cell lymphoma (DLBCL) who achieved post-treatment event-free survival for 24 months had only a minimally lower life expectancy.

PET Scans Inform, Improve Treatment in Esophageal Cancer

PET Scans Inform, Improve Treatment in Esophageal Cancer

Altering chemotherapy during neoadjuvant chemoradiotherapy based on response to induction chemotherapy by PET imaging can improve pathologic complete response.

Physical Activity Associated With Improved PFS, OS in Advanced CRC

Physical Activity Associated With Improved PFS, OS in Advanced CRC

Among patients with advanced colorectal cancer, greater total physical activity improved progression-free and overall survival.

FOLFIRI and XELIRI Are Safe, Well-tolerated in Metastatic Colorectal Cancer

FOLFIRI and XELIRI Are Safe, Well-tolerated in Metastatic Colorectal Cancer

Despite differences in the safety profiles and rates of adverse events, both FOLFIRI and XELIRI were safe and well-tolerated as second-line therapy.

Watch-and-Wait Safe for Patients With Rectal Cancer

Watch-and-Wait Safe for Patients With Rectal Cancer

Omitting surgery and using a watch-and-wait approach does not compromise outcomes for selected patients with advanced rectal cancer.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters